European Patent Office

T 2395/22 vom 31.01.2024

Europäischer Rechtsprechungsidentifikator
ECLI:EP:BA:2024:T239522.20240131
Datum der Entscheidung
31. Januar 2024
Aktenzeichen
T 2395/22
Antrag auf Überprüfung von
-
Anmeldenummer
16157001.5
Verfahrenssprache
Englisch
Verteilung
Nicht verteilt (D)
Amtsblattfassungen
Keine AB-Links gefunden
Weitere Entscheidungen für diese Akte
-
Zusammenfassungen für diese Entscheidung
-
Bezeichnung der Anmeldung
FORMULATION OF BORONIC ACID COMPOUNDS
Name des Antragstellers
The United States of America, represented by the
Secretary, Department of Health and Human Services
Name des Einsprechenden
Teva Pharmaceutical Industries Ltd
Fresenius Kabi Deutschland GmbH
Pfizer Inc.
LEK Pharmaceuticals d.d.
Synthon BV
PENTAFARMA, Sociedade Técnico-Medicinal, SA
KRKA, d.d., Novo mesto
Zentiva k.s.
Accord Healthcare
Dr. Reddy's Laboratories Ltd./ Betapharm
Arzneimittel GmbH
Generics [UK] Ltd
Kammer
3.3.02
Leitsatz
-
Relevante Rechtsnormen
European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 11Rules of procedure of the Boards of Appeal Art 12(3)Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 12(5)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(2)
Schlagwörter
Novelty with regard to an alleged public prior use
Novelty - obligation to confidentiality
Added subject-matter
Sufficiency of disclosure
Inventive step
Orientierungssatz
-
Zitierende Akten
T 1913/21T 1178/23

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the opposition division

with the order to maintain the patent in amended

form with the claims according to auxiliary

request 5a filed on 30 January 2024 at the oral

proceedings before the board, and a description

to be adapted thereto if appropriate.